GHRH comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-11-24. Numbers and descriptions here follow the published literature rather than marketing material.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
=== Applications in government === Several government bodies in the United States and United Kingdom have deployed or announced the deployment of agents at the local and national level. The city of Kyle, Texas deployed an AI agent from Salesforce in March 2025 for 311 customer service. In November 2025, the Internal Revenue Service stated that it would deploy Salesforce AI agents for the Office of Chief Counsel, Taxpayer Advocate Services, and the Office of Appeals. That same month, Staffordshire Police announced that they would trial Agentforce agents for handling non-emergency 101 calls in the United Kingdom starting in 2026. In December 2025, the Department of Neighborhoods in Detroit, Michigan, partnered with a local business to deploy a customer service AI agent in two city districts. In February 2025, Thomas Shedd, the director of the Technology Transformation Services, proposed using AI coding agents across the United States federal government. In April 2025, a recruiter for the Department of Government Efficiency proposed using AI agents to automate the work of about 70,000 United States federal government employees as part of a startup with funding from OpenAI and a partnership agreement with Palantir. This proposal was criticized by experts for its impracticality and the lack of corresponding widespread adoption by businesses.
Upon release, the album was met with widespread acclaim from critics. According to the review aggregator Metacritic, Let God Sort Em Out received "universal acclaim" based on a weighted average score of 83 out of 100 from eleven critic scores. Alexis Petridis of The Guardian gave the album a perfect score and called it "as strong a restatement of Clipse's skills and power as you could wish for". The lyrical versatility was praised ("Great lines abound, from the chilling to the laugh-out-loud"), as were the duo's chemistry; the guest appearances, which were said to have "step[ped] up" without stealing the show; and the "inspired" production. He concluded by declaring it one of the best albums of the year. Tom Breihan of Stereogum shared similar sentiments when reviewing the album for the publication's Premature Evaluation column, commenting on its "minimal, stabbing intensity" that he likened to Clipse's second album, Hell Hath No Fury (2006). Lyrically, he also praised the duo's chemistry with the featured guests—Stove God Cooks and Ab-Liva in particular—and Malice's presence, which "still has the gravitational force of a black hole". Niall Smith of Clash gave the album a nine out of ten and described the lyrics as a balance between the duo's old style and introspection on "maturity, perspective[,] and loss". Smith felt that the album's most impressive aspect was the guest appearances; although he felt some of Williams's choruses were "shakier moments", they were mostly redeemed by Clipse's "synergy".
Known spacecraft/nuclear power systems and their fate. Systems face a variety of fates, for example, Apollo's SNAP-27 were left on the Moon. Some other spacecraft also have small radioisotope heaters, for example each of the Mars Exploration Rovers have a 1 watt radioisotope heater. Spacecraft use different amounts of material, for example MSL Curiosity has 4.8 kg of plutonium-238 dioxide.
== Function == The protein encoded by this gene is an enzyme that belongs to the subtilisin-like proprotein convertase family. The members of this family are proprotein convertases that process latent precursor proteins into their biologically active products. This encoded protein is a calcium-dependent serine endoprotease that can efficiently cleave precursor proteins at their paired basic amino acid processing sites. Some of its substrates are: proparathyroid hormone, transforming growth factor beta 1 precursor, proalbumin, pro-beta-secretase, membrane type-1 matrix metalloproteinase, beta subunit of pro-nerve growth factor and von Willebrand factor. A furin-like pro-protein convertase has been implicated in the processing of RGMc (also called hemojuvelin), a gene involved in a severe iron-overload disorder called juvenile hemochromatosis. Both the Ganz and Rotwein groups demonstrated that furin-like proprotein convertases (PPC) are responsible for conversion of 50 kDa HJV to a 40 kDa protein with a truncated COOH-terminus, at a conserved polybasic RNRR site. This suggests a potential mechanism to generate the soluble forms of HJV/hemojuvelin (s-hemojuvelin) found in the blood of rodents and humans. The furin substrates and the locations of furin cleavage sites in protein sequences can be predicted by two bioinformatics methods: ProP and PiTou.
In 2003, Burger King hired the Miami-based advertising agency Crispin Porter + Bogusky (CP+B), which completely reorganized its advertising with a series of new campaigns. CP+B was known for having a hip, subversive tack when creating campaigns for its clients, exactly what BK was looking for. Their strategy centered on a redesigned Burger King character used during the 1970s/1980s Burger King Kingdom children's advertising campaign as a caricatured variation, now simply called "the King". While highly successful, some of CP+B's commercials were derided for perceived sexism or cultural insensitivity. Burger King's new owner, 3G Capital, later terminated the relationship with CP+B in 2011 and moved its advertising to McGarryBowen to begin a new product-oriented campaign with expanded demographic targeting. Additionally, CP+B created a series of new characters like the Subservient Chicken and the faux nu-metal band Coq Roq, featured in a series of viral web-based advertisements on sites such as MySpace and various Burger King corporate pages, to complement various television and print promotional campaigns. One of the more successful promotions that CP+B devised was the creation of a series of three advergames for the Xbox 360. Created by UK-based Blitz Games and featuring company celebrity spokesman Brooke Burke, the games sold more than 3.2 million copies, placing them as one of the top selling games along with another Xbox 360 hit, Gears of War.
Sources: en.wikipedia.org
== History and uses == Azinphos-methyl is a neurotoxin derived from nerve agents developed during World War II. It was first registered in the US in 1959 as an insecticide and is also used as active ingredient in organophosphate (OP) pesticides. It is not registered for consumer or residential use. It has been linked to health problems of farmers who apply it, and the U.S. Environmental Protection Agency (EPA) considered a denial of reregistration, citing, “concern to farm workers, pesticide applicators, and aquatic ecosystems. The use of AZM has been fully banned in the USA since 30 September 2013, ending a phase-out period of twelve years. Azinphos-methyl has been banned in the European Union since 2006 and in Turkey since 2013. The New Zealand Environmental Risk Management Authority made a decision to phase out azinphos-methyl over a five-year period starting from 2009. In 2014, it was still used in Australia and partly in New Zealand.
John Kenneth Stille subsequently reported the coupling of a variety of alkyl tin reagents in 1978 with numerous aryl and acyl halides under mild reaction conditions with much better yields (76%–99%). Stille continued his work in the 1980s on the synthesis of a multitude of ketones using this broad and mild process and elucidated a mechanism for this transformation.
=== Film adaptation === A film adaptation has been in development hell since 2013, and it was reported on May 25, 2021, that the project is still in development by J.J. Abrams and Bad Robot and the script has been written. As of 2022, J.J. Abrams continued to express interest in bringing Portal to film. In 2026, Kane Parsons also expressed interest in directing a Portal film.
Thomas's body was brought back to Wales for burial in the village churchyard at Laugharne. Thomas's funeral, which Brinnin did not attend, took place at St Martin's Church in Laugharne on 24 November. Six friends from the village carried Thomas's coffin. Caitlin, without her customary hat, walked behind the coffin with his childhood friend Daniel Jones at her arm and her mother by her side. The procession to the church was filmed and the wake took place at Brown's Hotel. Thomas's fellow poet and long-time friend Vernon Watkins wrote The Times obituary. Though Thomas died intestate, with assets worth £100, substantial royalties would accrue from sales of his work, with half the proceeds allocated to Caitlin and half to the three children. A trust was established to administer the estate and protect the copyright of Thomas's work. Trustees included Daniel Jones, Wynford Vaughan Thomas and, in an unlikely development given his low opinion of Thomas, Kingsley Amis, who was appointed at the behest of the Thomas family solicitor and administrator of the trust, Stuart Thomas. After Caitlin, troubled by painful memories, left Laugharne to live in Italy, the Thomas family home, the Boathouse, became the home of her mother-in-law, Florence, for the last five years of her life. It was subsequently purchased by the trust from Margaret Taylor on behalf of Caitlin who sold it on to an educational charity before it was eventually acquired by Carmarthenshire County Council and opened to the public as a tourist attraction.
Sources: en.wikipedia.org
A 2023 meta-analysis of 16 RCTs found that transcranial direct current stimulation (tDCS) of over 4 weeks can decrease pain in patients with fibromyalgia. A 2021 meta-analysis of multiple intervention types concluded that magnetic field therapy and transcranial magnetic stimulation may diminish pain in the short-term, but conveyed an uncertainty about the relevance of the result. Several 2022 meta-analyses focusing on transcranial magnetic stimulation found positive effects on fibromyalgia. Repetitive transcranial magnetic stimulation improved pain in the short-term and quality of life after 5–12 weeks. Repetitive transcranial magnetic stimulation did not improve anxiety, depression, and fatigue. Transcranial magnetic stimulation to the left dorsolateral prefrontal cortex was also ineffective. A systematic review of EEG neurofeedback for the treatment of fibromyalgia found most treatments showed significant improvements of the main symptoms of the disease. However, the protocols were so different, and the lack of controls or randomization impede drawing conclusive results.
In contrast with gases, there is no simple yet accurate picture for the molecular origins of viscosity in liquids. At the simplest level of description, the relative motion of adjacent layers in a liquid is opposed primarily by attractive molecular forces acting across the layer boundary. In this picture, one (correctly) expects viscosity to decrease with increasing temperature. This is because increasing temperature increases the random thermal motion of the molecules, which makes it easier for them to overcome their attractive interactions. Building on this visualization, a simple theory can be constructed in analogy with the discrete structure of a solid: groups of molecules in a liquid are visualized as forming "cages" which surround and enclose single molecules. These cages can be occupied or unoccupied, and stronger molecular attraction corresponds to stronger cages. Due to random thermal motion, a molecule "hops" between cages at a rate which varies inversely with the strength of molecular attractions. In equilibrium these "hops" are not biased in any direction. On the other hand, in order for two adjacent layers to move relative to each other, the "hops" must be biased in the direction of the relative motion. The force required to sustain this directed motion can be estimated for a given shear rate, leading to
Clayton (1956), fiction writer, novelist Robert Silverberg (1956), science fiction writer, recipient of the Damon Knight Memorial Grand Master Award in 2004 Paul Zweig (1956), poet, memoirist, 1976 Guggenheim Fellow George Bellak (1957), television writer Richard P. Brickner (1957), writer, 1983 Guggenheim Fellow Raymond Federman (1957), French–American novelist and academic; author, Double or Northing Lawrence Shainberg (1958), writer of Zen Buddhism Jerome Charyn (1959), novelist Jay Neugeboren (1959), novelist, essayist, short story writer Robert T.
Whereas medical school teaches physicians a broad range of medical knowledge, basic clinical skills, and supervised experience practicing medicine in a variety of fields, medical residency gives in-depth training within a specific branch of medicine.
8-Hydroxyamoxapine is an active metabolite of the antidepressant drug amoxapine (Asendin). It contributes to amoxapine's pharmacology. It is a serotonin-norepinephrine reuptake inhibitor (SNRI) with similar norepinephrine, but more serotonin, reuptake inhibition as its parent compound. It plays a part in balancing amoxapine's ratio of serotonin to norepinephrine transporter blockage.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.